Angiographic changes after bevacizumab.
Ikuno
Yasushi
Y
Soga
Kaori
K
Wakabayashi
Taku
T
Gomi
Fumi
F
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015862:Choroid Diseases / Q000139:chemically induced* / Q000175:diagnosis; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography / Q000187:drug effects*; D006801:Humans; D007208:Indocyanine Green; D007267:Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications; D055213:Retinal Pigment Epithelium / Q000187:drug effects* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D007208:Indocyanine Green